AVP receptor antagonists as aquaretics: Review and assessment of clinical data

Cleveland Clinic Journal of Medicine

Volumn 73, Issue SUPPL.3, 2006, Pages

  Verbalis, Joseph G ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 FLUORO 2 METHYL N (4 (5H PYRROLO(2,1 C) (1,4)BENZODIAZEPIN 10 (11H) YLCARBONYL) 3 CHLOROPHENYL)BENZAMIDE; 5-FLUORO-2-METHYL-N-(4-(5H-PYRROLO(2,1-C)-(1,4)BENZODIAZEPIN-10-(11H)-YLCARBONYL)-3-CHLOROPHENYL)BENZAMIDE; ARGIPRESSIN; AZEPINE DERIVATIVE; BENZAMIDE DERIVATIVE; BENZAZEPINE DERIVATIVE; CONIVAPTAN; TOLVAPTAN; VASOPRESSIN RECEPTOR;

DRUG ANTAGONISM; DRUG EFFECT; ELECTROLYTE BALANCE; HUMAN; HYPONATREMIA; PATHOPHYSIOLOGY; REVIEW;

ARGININE VASOPRESSIN; AZEPINES; BENZAMIDES; BENZAZEPINES; HUMANS; HYPONATREMIA; RECEPTORS, VASOPRESSIN; WATER-ELECTROLYTE BALANCE;

EID: 33750596452     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.73.Suppl_3.S24     Document Type: Review

References (28)

1. Verbalis JG. The syndrome of inappropriate antidiuretic hormone secretion and other hypoosmolar disorders. In: Schrier RW, ed. Diseases of the Kidney and Urinary Tract. Vol 3. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:2511-2548.
2. Verbalis JG. Vasopressin V2 receptor antagonists. J Mol Endocrinol 2002; 29:1-9.
3. Bichet DG. Vasopressin receptors in health and disease. Kidney Int 1996; 49:1706-1711.
4. Tanoue A, Ito S, Honda K, et al. The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. J Clin Invest 2004; 113:302-309.
5. Thibonnier M, Conarty DM, Preston JA, Wilkins PL, Berti- Mattera LN, Mattera R. Molecular pharmacology of human vasopressin receptors. Adv Exp Med Biol 1998; 449:251-276.
6. Robinson AG, Verbalis JG. The posterior pituitary. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, eds. Textbook of Endocrinology. 10th ed. Philadelphia, PA: Elsevier; 2002:281-329.
7. Janicic N, Verbalis JG. Evaluation and management of hypo-osmolality in hospitalized patients. Endocrinol Metab Clin North Am 2003; 32:459-481.
8. Schrier RW. Water and sodium retention in edematous disorders: role of vasopressin and aldosterone. Am J Med 2006; 119(7 Suppl 1):S47-S53.
9. Sonnenblick M, Friedlander Y, Rosin AJ. Diuretic-induced severe hyponatremia. Review and analysis of 129 reported patients. Chest 1993; 103:601-606.
10. Greenberg A. Diuretic complications. Am J Med Sci 2000; 319:10-24.
11. Upadhyay A, Jaber BL, Madias NE. Incidence and prevalance of hyponatremia. Am J Med 2006; 119(7 Suppl 1):S30-S35.
12. Bichet DG, Razi M, Lonergan M, et al. Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus. N Engl J Med 1988; 318:881-887.
13. Knepper MA. Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin. Am J Physiol 1997; 272(1 Pt 2):F3-F12.
14. Nielsen S, Kwon TH, Christensen BM, Promeneur D, Frokiaer J, Marples D. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 1999; 10:647-663.
15. Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int 2006; 69:2124-2130.
16. Painchaud CA, Ghazzi MM, Selaru P, Bichet DG, Chartier KK, Udelson JE. Urinary water clearance after infusion of conivaptan, a combined vasopressin V1A and V2 receptor antagonist, in patients with NYHA class III/IV heart failure. Poster presented at: Annual Meeting of the American Heart Association; November 12-15, 2000; Chicago, IL. Also presented at: European Society of Cardiology Congress; September 1-5, 2001; Stockholm, Sweden.
17. Lee CR, Watkins ML, Patterson JH, et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J 2003; 146:9-18.
18. Ghali JK, Koren MJ, Taylor JR, et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 2006; 91:2145-2152.
19. Verbalis JG, Bisaha JG, Smith N. Novel vasopressin V1A and V2 antagonist (conivaptan) increases serum sodium concentration and effective water clearance in patients with hyponatremia [abstract]. J Card Fail 2004; 10(4 Suppl 1):S27. Abstract 036.
20. Vaprisol (conivaptan hydrochloride injection) prescribing information. Deerfield, IL: Astellas Pharma US, Inc; February 2006.
21. Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebocontrolled trial. Hepatology 2003; 37:182-191.
22. Gerbes AL, Gulberg V, Gines P, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double- blind multicenter trial. Gastroenterology 2003; 124:933-939.
23. Soupart A, Gross P, Legros JJ, et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with SR 121 463 B, an orally active, nonpeptide, vasopressin V-2 receptor antagonist [abstract]. J Am Soc Nephrol 2004; 15:563A. Abstract SU-PO140.
24. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003; 107:2690-2696.
25. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291:1963-1971.
26. Gheorghiade M, Gottlieb SS, Udelson JE, et al. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol 2006; 97:1064-1067.
27. Gross P, Verbalis J, Berl T, et al. Hyponatremia management with a once-daily, oral vasopressin V2 receptor antagonist for up to one year: first report of the tolvaptan SALT 2 study. Paper presented at: American Society of Nephrology Congress; November 11, 2005; Philadelphia, PA.
28. Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 2006; 119:71.e1-8.